JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feldpausch, D. L.
Right arrow Articles by Merchant, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feldpausch, D. L.
Right arrow Articles by Merchant, K. M.

Vol. 286, Issue 1, 497-508, July 1998

The Role of Dopamine D4 Receptor in the Induction of Behavioral Sensitization to Amphetamine and Accompanying Biochemical and Molecular Adaptations

Dawna L. Feldpausch, Lana M. Needham, Michael P. Stone, John S. Althaus, Bryan K. Yamamoto, Kjell A. Svensson and Kalpana M. Merchant

Central Nervous System Diseases Research, Pharmacia & Upjohn, Inc., Kalamazoo, Michigan (D.L.F., L.M.N., M.P.S., J.S.A., K.A.S., K.M.M.) and Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio (B.K.Y.)

Our studies examined the role of dopamine D4 receptors in the induction of behavioral sensitization to amphetamine (Amp) and accompanying neurochemical and molecular adaptive responses using a highly selective D4 antagonist, PNU-101387G. Behavioral sensitization to an acute challenge of Amp (2 mg/kg, s.c.) was observed in rats pretreated with five daily doses of Amp (2 mg/kg/d, s.c.) followed by 7-day withdrawal. Interestingly, coadministration of PNU-101387G with Amp during pretreatment completely blocked the sensitized response to an acute Amp challenge. The behavioral sensitization and its blockade by the D4 antagonist were observed in the absence of significant differences in cerebellar Amp levels among the various pretreatment groups. Accompanying behavioral sensitization were two postsynaptic neuroadaptive responses: reduction in the ability of Amp to induce c-fos gene expression in the infralimbic/ventral prelimbic cortex and NT/N mRNA in the accumbal shell. However, concurrent blockade of D4 receptors during Amp pretreatment prevented the refractoriness in c-fos and NT/N responsiveness to acute Amp. We observed also a presynaptic neuroplastic response associated with the behavioral sensitization: a significant augmentation in the ability of Amp to increase extracellular dopamine concentrations in the nucleus accumbens shell. As with the behavioral sensitization and associated postsynaptic adaptive responses, concurrent administration of PNU-101387G with Amp during pretreatment blocked the augmentation in Amp-induced dopamine release. Taken together, these data demonstrate that dopamine D4 receptors play an important role in the induction of behavioral sensitization to Amp and accompanying adaptations in pre- and postsynaptic neural systems associated with the mesolimbocortical dopamine projections.


0022-3565/98/2861-0497$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Arch Gen PsychiatryHome page
A. L. Brody, M. A. Mandelkern, R. E. Olmstead, D. Scheibal, E. Hahn, S. Shiraga, E. Zamora-Paja, J. Farahi, S. Saxena, E. D. London, et al.
Gene Variants of Brain Dopamine Pathways and Smoking-Induced Dopamine Release in the Ventral Caudate/Nucleus Accumbens.
Arch Gen Psychiatry, July 1, 2006; 63(7): 808 - 816.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
R. Ventura, S. Cabib, A. Alcaro, C. Orsini, and S. Puglisi-Allegra
Norepinephrine in the Prefrontal Cortex Is Critical for Amphetamine-Induced Reward and Mesoaccumbens Dopamine Release
J. Neurosci., March 1, 2003; 23(5): 1879 - 1885.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
E. B. Binder, B. Kinkead, M. J. Owens, and C. B. Nemeroff
Neurotensin and Dopamine Interactions
Pharmacol. Rev., December 1, 2001; 53(4): 453 - 486.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Rubinstein, C. Cepeda, R. S. Hurst, J. Flores-Hernandez, M. A. Ariano, T. L. Falzone, L. B. Kozell, C. K. Meshul, J. R. Bunzow, M. J. Low, et al.
Dopamine D4 Receptor-Deficient Mice Display Cortical Hyperexcitability
J. Neurosci., June 1, 2001; 21(11): 3756 - 3763.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.